II2 Stock Overview A medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
InspireMD, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for InspireMD Historical stock prices Current Share Price US$2.56 52 Week High US$3.12 52 Week Low US$1.70 Beta 0.98 1 Month Change -6.57% 3 Month Change 7.56% 1 Year Change 7.56% 3 Year Change -5.88% 5 Year Change -81.84% Change since IPO -100.00%
Recent News & Updates
Craig Shore Decides to Retire as Chief Financial Officer of InspireMD, Inc Dec 12
Inspiremd Announces First Patient Enrolled in the Cguardians Ii Pivotal Study of the Cguard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures Dec 10
InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors Nov 26
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) Nov 13
InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 04
InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System Oct 07 See more updates
Craig Shore Decides to Retire as Chief Financial Officer of InspireMD, Inc Dec 12
Inspiremd Announces First Patient Enrolled in the Cguardians Ii Pivotal Study of the Cguard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures Dec 10
InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors Nov 26
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) Nov 13
InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 04
InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System Oct 07
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System Sep 16
Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023) Aug 06
New major risk - Share price stability Jul 31
InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023) May 15
InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024 May 09
Insufficient new directors May 01
InspireMD, Inc., Annual General Meeting, Jun 10, 2024 Apr 20
Full year 2023 earnings released: US$0.82 loss per share (vs US$2.35 loss in FY 2022) Mar 07
InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024 Feb 29
Insider recently bought €116k worth of stock Dec 05
Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial Nov 02
InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
InspireMD, Inc. Announces Management Appointments Oct 05
Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.59 loss in 2Q 2022) Aug 08
InspireMD, Inc., Annual General Meeting, Sep 13, 2023 Jul 29
InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial Jun 28 InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors May 17
InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023 May 06
Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.53 loss in 3Q 2021) Nov 10
InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Insider recently bought €67k worth of stock Aug 23
Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.46 loss in 2Q 2021) Aug 10
InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 03
InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor Jul 15
InspireMD, Inc., Annual General Meeting, Aug 31, 2022 Jul 06
First quarter 2022 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2021) May 12
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 09
InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application Mar 01
InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Feb 24
InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor Feb 16
Insider recently bought €88k worth of stock Nov 19
Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020) Nov 10
Insider recently bought €79k worth of stock Aug 28
Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020) Aug 11
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS Jul 25
First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020) May 12
Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019) Mar 10
Revenue misses expectations Mar 10
InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021 Mar 03
InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States Feb 25
InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States Feb 10
New 90-day high: €0.88 Feb 10
InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million. Feb 05
InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China Feb 04
New 90-day high: €0.64 Jan 22
New 90-day high: €0.50 Jan 06
Revenue beats expectations Nov 10
Third quarter 2020 earnings released: US$0.064 loss per share Nov 10
Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing Nov 04
InspireMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Nov 03
InspireMD, Inc. announced that it has received $0.1 million in funding Oct 20
InspireMD Announces Gary S. Roubin, M.D., Ph.D., to Join Board of Directors Oct 14
InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives Oct 07
InspireMD, Inc. to Report Q3, 2019 Results on Nov 12, 2019 Sep 26
New 90-day low: €0.28 Sep 23
InspireMD, Inc.(AMEX:NSPR) dropped from S&P TMI Index Sep 21
New 90-day low - €0.32 Sep 02
New 90-day low - €0.35 Aug 15
InspireMD Regains Compliance with NYSE Listing Standards Aug 11
InspireMD, Inc. to Report Q2, 2020 Results on Aug 05, 2020 Jul 31 Shareholder Returns II2 DE Medical Equipment DE Market 7D -11.1% -1.6% 0.3% 1Y 7.6% -9.1% 6.9%
See full shareholder returns
Return vs Market: II2 matched the German Market which returned 7.2% over the past year.
Price Volatility Is II2's price volatile compared to industry and market? II2 volatility II2 Average Weekly Movement 9.5% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: II2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: II2's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.
Show more InspireMD, Inc. Fundamentals Summary How do InspireMD's earnings and revenue compare to its market cap? II2 fundamental statistics Market cap €67.46m Earnings (TTM ) -€27.15m Revenue (TTM ) €6.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) II2 income statement (TTM ) Revenue US$6.82m Cost of Revenue US$5.28m Gross Profit US$1.54m Other Expenses US$29.78m Earnings -US$28.24m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.08 Gross Margin 22.61% Net Profit Margin -413.96% Debt/Equity Ratio 0%
How did II2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 18:52 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources InspireMD, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raymond Myers Benchmark Company Keay Nakae Chardan Capital Markets, LLC Vernon Bernardino H.C. Wainwright & Co.
Show 7 more analysts 
